Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
Those wanting to see whether the US government was right to give Novavax $1.6bn two weeks ago will have to wait a little longer.
The coronavirus vaccine race now features three front runners with clinical data, and at least one boasts impressive T-cell responses.
A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.
But the trade-off between efficacy and tolerability could limit mRNA-1273’s use to those who need it least.
An Avastin combination draws a blank in the Imagyn-050 study. Will a combo with a Parp inhibitor fare any better?
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Daridorexant can't reach the heights of its first pivotal study win, but a pooled analysis could still save it.